A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS. Description of Business We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. We have developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. The excipients in the formulation are not intended to modify the proteins chemically or biologically, and the dosage form is designed to be safe to ingest. On January 11, 2023, we announced that the Phase 3 oral insulin trial (ORA-D-013-1) did not meet its primary or secondary endpoints. As a result, we terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 0 | - |
| Net Income | 44M | 5.1M | -37M | -23M | -12M | -14M |
| EPS | $1.00 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 |
| Free Cash Flow | -11M | -11M | -28M | -22M | -13M | -13M |
| ROIC | -7.0% | 3.0% | -24.1% | -13.8% | - | - |
| Gross Margin | - | 0.0% | - | 0.0% | 0.0% | - |
| Debt/Equity | 0.00 | 0.36 | 0.00 | 0.07 | - | - |
| Dividends/Share | $0.00 | $0.00 | - | $0.00 | $0.00 | - |
| Operating Income | -13M | -16M | -41M | -24M | -12M | -15M |
| Operating Margin | 0.0% | 0.0% | - | 0.0% | 0.0% | - |
| ROE | 21.6% | 3.2% | -23.0% | -13.8% | - | - |
| Shares Outstanding | 40M | 36M | 39M | 38M | 24M | 17M |
ORAMED PHARMACEUTICALS INC. passes 0 of 9 quality checks, indicating weak fundamentals.
ORAMED PHARMACEUTICALS INC. trades at 3.3x trailing earnings, compared to its 15-year median P/E of 5.9x, suggesting it is currently Cheap relative to its historical range. At current prices, the estimated annualized return to fair value is -3.5%.
ORAMED PHARMACEUTICALS INC. (ORMP) has a current P/E ratio of 3.3, compared to its historical median P/E of 5.9. The stock is currently considered Cheap based on its historical valuation range.
ORAMED PHARMACEUTICALS INC. (ORMP) has a 5-year average return on invested capital (ROIC) of -11.6%. This is below average and may indicate limited pricing power.
ORAMED PHARMACEUTICALS INC. (ORMP) has a market capitalization of $151M. It is classified as a small-cap stock.
ORAMED PHARMACEUTICALS INC. (ORMP) does not currently pay a regular dividend.
Based on historical P/E analysis, ORAMED PHARMACEUTICALS INC. (ORMP) appears cheap. The current P/E of 3.3 is 44% below its historical median of 5.9. The estimated fair value CAGR (P/E method) is -3.5%.
ORAMED PHARMACEUTICALS INC. (ORMP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ORAMED PHARMACEUTICALS INC. (ORMP) generated $-11 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ORAMED PHARMACEUTICALS INC. (ORMP) has a debt-to-equity ratio of 0.36. This indicates a conservatively financed balance sheet.
ORAMED PHARMACEUTICALS INC. (ORMP) reported earnings per share (EPS) of $0.14 in its most recent fiscal year.
ORAMED PHARMACEUTICALS INC. (ORMP) has a return on equity (ROE) of 3.2%. This indicates moderate shareholder returns.
The Ledger Terminal provides 12 years of financial data for ORAMED PHARMACEUTICALS INC. (ORMP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ORAMED PHARMACEUTICALS INC. (ORMP) has a book value per share of $4.51, based on its most recent annual SEC filing.